Back to search

Aristotle University Of Thessaloniki (AUTH)

Μελέτη της έκφρασης γονιδίων φαρμακευτικής αντοχής στην παιδική λευχαιμία

Abstract

dc:description

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Despite the progress that has been achieved in treatment of childhood ALL a significant percentage of children will eventually relapse. Treatment failure in these patients is mainly attributable to the occurrence of resistance to structurally and functionally unrelated drugs, called multidrug resistance (MDR). The major mechanism is the overexpression of multi drug resistance gene (MDR1), the multi drug resistance related protein gene (MRP1), the breast cancer resistance protein (BCRP) and the lung resistance gene (LRP) which encode proteins acting as drug efflux pumps resulting in low intracellular accumulation of chemotherapeutic drugs. Aim of this prospective study was the analysis of expression of mRNA of genes implicated in the mechanism of multidrug resistance such as MDR1, MRP1, BCRP and LRP in relation with response to induction chemotherapy and relapse and their correlation with each other as well as with pre-treatment laboratory and clinical characteristics. Material and methods: We studied prospectively 49 children with ALL (26 boys and 23 girls) with median age of 5.5 years (range: 15 months to 12.5 years), treated with the BFM95 chemotherapy protocol. As controls we used bone marrow (BM) mononuclear cells from 7 children who underwent a BM biopsy for diagnostic purposes and was negative for leukemia. Total RNA was isolated from BM samples at initial diagnosis with an excess of 90% leukemic blasts and relapse. The expression of MDR-genes and the housekeeping b-actin gene was detected by RT-PCR using the appropriate primers. The relative mRNA expression of each MDR-gene was calculated using the following formula: Expression Index (EI): MDR-gene product / b-actin PCR product. Results: Statistically significant correlation was found between the EI of MRP or LRP with each other and MDR1 (p<0.05). We found significantly higher mean EI for MDR1 at relapse at four paired samples compared with diagnosis. High EI for the MDR1 gene was found in 18 patients (36.7%) and their prognosis was significantly worse compared with those with low EI ((Event free survival (EFS): 55.56% vs 86.67%, p log rank=0.03). High MDR1 gene expression was independent of initial white blood cell (wbc) count, immunophenotype, NCI and BFM risk classification. Conclusions: The expression of the MDR1 gene is a biologic marker helpful in predicting the risk of treatment failure and it is useful to be evaluated along with the other prognostic factors.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2007

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kourti, Maria
  • Κούρτη, Μαρία

Subjects

dc:subject × 17

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/20375

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kourti, Maria; Κούρτη, Μαρία. Μελέτη της έκφρασης γονιδίων φαρμακευτικής αντοχής στην παιδική λευχαιμία. Aristotle University Of Thessaloniki (AUTH), 2007. http://hdl.handle.net/10442/hedi/20375